Why There's Still No FDA-Approved Medication for Cannabis Addiction
Despite increasing cannabis use disorder prevalence, developing medications has been hampered by difficulty creating animal models and disagreement about whether treatment should aim for abstinence or reduced use.
Quick Facts
What This Study Found
The translational pipeline from preclinical to clinical CUD pharmacotherapy is hindered by challenges in establishing robust animal self-administration models and fundamental questions about efficacy endpoints (abstinence vs. reduction in use).
Key Numbers
No FDA-approved medications for CUD; research lags compared to other substance use disorders; key challenge: animal models of cannabinoid self-administration remain difficult to establish.
How They Did This
Comprehensive review evaluating the translational pipeline for cannabis use disorder medications, from preclinical models through human laboratory studies to randomized controlled clinical trials.
Why This Research Matters
Cannabis use disorder affects millions but has zero FDA-approved treatments — understanding why the pipeline is stuck is essential for breaking through to effective medications.
The Bigger Picture
The fundamental debate about treatment goals — complete abstinence vs. harm reduction through reduced use — shapes not just clinical practice but which drug candidates advance through trials.
What This Study Doesn't Tell Us
Review scope focused on pharmacotherapy; doesn't address behavioral or combined approaches; rapidly evolving field means some recent developments may not be captured.
Questions This Raises
- ?Could adaptive trial designs that accept reduced use as an endpoint accelerate CUD medication development?
- ?What preclinical model innovations could improve translational validity?
Trust & Context
- Key Stat:
- Evidence Grade:
- Authoritative review from leading CUD researchers published in a top behavioral neuroscience series, comprehensively covering the translational pipeline.
- Study Age:
- Published in 2026, providing the most current assessment of CUD pharmacotherapy development challenges.
- Original Title:
- Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.
- Published In:
- Current topics in behavioral neurosciences, 76, 249-296 (2026)
- Authors:
- Bedillion, Margaret F(3), Moore, Catherine F(6), Weerts, Elise M(10), Arout, Caroline A, Harris, Hannah M, Haney, Margaret
- Database ID:
- RTHC-08112
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is there medication for cannabis addiction?
Currently, there are no FDA-approved medications specifically for cannabis use disorder. Multiple candidates are being studied, but challenges in both preclinical and clinical research have slowed progress.
Why is it so hard to develop cannabis addiction treatments?
Key challenges include difficulty creating reliable animal models of cannabis self-administration and disagreement about whether success means complete abstinence or just reduced, less harmful use.
Read More on RethinkTHC
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- cross-addiction-quit-weed-start-drinking
- is-weed-addictive
- is-weed-addictive-science
- quitting-weed-and-alcohol
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
- cannabis-recovery-community-support-group-compare
- thc-and-weightlifting-muscle-growth-recovery
- cannabis-recovery-devotional-30-days-scripture
- celebrate-recovery-vs-marijuana-anonymous
Cite This Study
https://rethinkthc.com/research/RTHC-08112APA
Bedillion, Margaret F; Moore, Catherine F; Weerts, Elise M; Arout, Caroline A; Harris, Hannah M; Haney, Margaret. (2026). Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.. Current topics in behavioral neurosciences, 76, 249-296. https://doi.org/10.1007/7854_2025_598
MLA
Bedillion, Margaret F, et al. "Pharmacotherapy for Cannabis Use Disorder: Preclinical and Clinical Models.." Current topics in behavioral neurosciences, 2026. https://doi.org/10.1007/7854_2025_598
RethinkTHC
RethinkTHC Research Database. "Pharmacotherapy for Cannabis Use Disorder: Preclinical and C..." RTHC-08112. Retrieved from https://rethinkthc.com/research/bedillion-2026-pharmacotherapy-for-cannabis-use
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.